Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Paroxysmal and Persistent Atrial Fibrillation refractory eligible for AF ablation as per HRS/ECAS/EHRA consensus statement.\[23\] Paroxysmal AF is defined as two or more episodes of AF lasting less than 7 days in duration during the last 6 months before enrollment. Persistent AF is defined as AF lasting more than 7 days or requiring cardioversion for termination.~2. Hypertension (\>140/80 mm Hg) on treatment with at least 1 hypertensive medication.~3. GFR \>60ml/dl using Cockcroft- Gault equation~Exclusion Criteria:~1. Secondary causes of hypertension~2. Severe renal artery stenosis or dual renal arteries~3. Congestive heart failure with NYHA class III or IV status~4. EF\< 35%~5. LA Diameter \>6 cm~6. Previous AF ablation~7. Previous renal artery stent or angioplasty~8. Severe contrast allergy~9. Inability to give informed consent~10. Solitary kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AF Ablation alone (Type: ACTIVE_COMPARATOR): Clinical AF ablation performed as deemed appropriate by operator
- AF ablation with Renal Denervation (Type: EXPERIMENTAL): Renal denervation performed using the same ablation catheter after clinical AF ablation

Based on this trial design, predict the completion outcome and termination type (if applicable).